Shearman & Sterling represented Morgan Stanley & Co. LLC, BofA Securities , Inc. and Cowen and Company, LLC as representatives of the underwriters in connection with the offering by selling shareholders of 2,243,000 American Depositary Shares (ADSs), each representing one Class A ordinary share of Burning Rock Biotech Limited, which is listed on NASDAQ, for a total consideration of approximately $57.76 million.

Headquartered in China, Burning Rock Biotech Limited is a biotech company which focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients and cancer early detection.

The Team